-
Recombinant IDH1 (R132C) protein
Recombinant IDH1 (R132C) protein
- 中文名称：
- Recombinant IDH1 (R132C) protein
- 英文名称：
- Recombinant IDH1 (R132C) protein
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA59783
- 规格：
- 0.1 mg|1 mg|2x1 mg|3x1 mg|4x1 mg
- 保存建议：
- Recombinant proteins in solution are temperature sensitive and must be stored at -80 degree C to prevent degradation. Avoid repeated freeze/thaw cycles and keep on ice when not in storage.
Shipping Temp: Dry Ice
- 货期：
- 6-8周
- 纯度：
- N/A
- 产品形式：
- Recombinant IDH1 (R132C) protein is supplied at a concentration of 0.8ug/ul in 25mM Tris pH8.0, 300mM NaCl, 5% glycerol.
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 说明书：
Short Description: Recombinant IDH1 (R132C) protein was expressed in E Coli as the full-length protein (accession number AAH93020.1) with a point mutation Arg132Cys and a C-terminal 6xHis-tag. The molecular weight of the protein is 47.7 kDa. It is suitable for peroxisome and NADPH regulation assays, as well as for use in the study of enzyme kinetics, inhibitor screening, and selectivity profiling.
Background: IDH1 (Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic, also known as HEL-216, HEL-S-26, IDCD, IDH, IDP, IDPC, PICD) is a member of isocitrate dehydrogenases, which catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. IDH1 is the NADP(+)-dependent isocitrate dehydrogenase found in the cytoplasm and peroxisomes. It contains the PTS-1 peroxisomal targeting signal sequence. The presence of this enzyme in peroxisomes suggests roles in the regeneration of NADPH for intraperoxisomal reductions, such as the conversion of 2, 4-dienoyl-CoAs to 3-enoyl-CoAs, as well as in peroxisomal reactions that consume 2-oxoglutarate, namely the alpha-hydroxylation of phytanic acid. The cytoplasmic enzyme serves a significant role in cytoplasmic NADPH production. Mutations in human cytosolic isocitrate dehydrogenase I (IDH1) occur somatically in >70% of grade II-III gliomas and secondary glioblastomas, and in 8.5% of acute myeloid leukemias (AML). Mutations have also been reported in cancers of the colon and prostate. To date, mutations in at least four active site arginine residues IDH1 R100, IDH1 R132, IDH2 R140, and IDH2 R172 have been shown to result in the neomorphic production of R(-)-2-hydroxyglutarate (2HG), although these mutants lack the wild-type enzyme's ability to convert isocitrate to a-ketoglutarate (a-KG, 2OG). Among of them, IDH1 R100A is affected in adult glioma.
